Clinical Trial Update: Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating escalating IV doses of tilmanocept with SPECT imaging in subjects with and without rheumatoid arthritis; study completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tilmanocept (Tilmanocept)

Snippet

Sponsor: Navidea Biopharmaceuticals | Conditions: Arthritis, Rheumatoid | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-08-12